Prestige Consumer Healthcare (PBH) Projected to Post Quarterly Earnings on Wednesday

Prestige Consumer Healthcare (NYSE:PBH) is expected to be posting its Q4 2026 results before the market opens on Wednesday, May 13th. Analysts expect Prestige Consumer Healthcare to post earnings of $1.39 per share and revenue of $293.76 million for the quarter. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Individuals are encouraged to explore the company’s upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The business had revenue of $283.44 million during the quarter, compared to analysts’ expectations of $286.93 million. During the same period in the prior year, the business earned $1.22 EPS. The business’s quarterly revenue was down 2.4% on a year-over-year basis. On average, analysts expect Prestige Consumer Healthcare to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Stock Down 1.1%

PBH stock traded down $0.64 during midday trading on Wednesday, hitting $55.11. The company’s stock had a trading volume of 22,311 shares, compared to its average volume of 455,648. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare has a 52-week low of $51.24 and a 52-week high of $89.37. The firm has a market capitalization of $2.61 billion, a P/E ratio of 14.59, a PEG ratio of 1.65 and a beta of 0.40. The firm has a 50-day simple moving average of $60.83 and a 200-day simple moving average of $62.03.

Insider Buying and Selling

In related news, VP Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total transaction of $65,930.00. Following the sale, the vice president directly owned 41,048 shares in the company, valued at $2,706,294.64. This trade represents a 2.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PBH. Squarepoint Ops LLC increased its stake in Prestige Consumer Healthcare by 316.1% in the third quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock valued at $18,836,000 after purchasing an additional 229,311 shares during the period. Goldman Sachs Group Inc. increased its stake in Prestige Consumer Healthcare by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after purchasing an additional 120,965 shares during the period. Bank of America Corp DE increased its stake in Prestige Consumer Healthcare by 19.1% in the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after purchasing an additional 115,459 shares during the period. Man Group plc acquired a new position in Prestige Consumer Healthcare in the third quarter valued at $6,808,000. Finally, Raymond James Financial Inc. increased its stake in Prestige Consumer Healthcare by 15.7% in the third quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock valued at $39,807,000 after purchasing an additional 86,373 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Jefferies Financial Group decreased their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $76.50.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).